DelveInsight’s “Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Acute Ischemic Stroke, historical and forecasted epidemiology as well as the Acute Ischemic Stroke market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Acute Ischemic Stroke Market Research Report

• The increase in Acute Ischemic Stroke Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Acute Ischemic Stroke market is anticipated to witness growth at a considerable CAGR.
• As per DelveInsight analysis, in 2022, the total Acute Ischemic Stroke incident cases was around 1,608,975 in the 7MM. These cases are projected to increase during the forecast period (2023-2034).
• As per DelveInsight’s epidemiology model, acute ischemic stroke is seen more among males than in females in the 7MM. However, in the US, more number of females are affected with AIS than males.
• The leading Acute Ischemic Stroke Companies working in the market include Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medical Research Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech,, and others.
• Promising Acute Ischemic Stroke Pipeline Therapies in the various stages of development include UMC119-06, JTR-161, Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution, YM872 (zonampanel), t-PA (alteplase), Elezanumab, Intravenous ACT017 1000 mg, rhPro-UK, rt-PA, and others.
• April 2024: Penumbra Inc.- The objective of this study is to demonstrate the safety and efficacy of the Penumbra System including Thunderbolt Aspiration Tubing (Thunderbolt) in a population presenting with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO) who are eligible for mechanical thrombectomy.
• April 2024: Shionogi announced a study of Phase 2 clinical trials for Redasemtide. The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).

 

Discover which therapies are expected to grab the Acute Ischemic Stroke Market Share @ Acute Ischemic Stroke Market Outlook

 

Acute Ischemic Stroke Overview

An acute ischemic stroke occurs when there is a sudden disruption of blood flow to a specific part of the brain, leading to a lack of oxygen and nutrients to that area. This disruption is typically caused by a blockage in one of the brain’s blood vessels, which can be due to a blood clot or an atherosclerotic plaque (a buildup of fatty deposits in the arteries). As a result, brain cells in the affected area begin to die, leading to a range of neurological symptoms.re.

 

Acute Ischemic Stroke Epidemiology Insights

The epidemiology section of Acute Ischemic Stroke offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total Acute Ischemic Stroke Incident Cases
• Acute Ischemic Stroke Gender-specific Cases
• Acute Ischemic Stroke Age-specific Cases
• Acute Ischemic Stroke Type-specific Cases

 

Download the report to understand which factors are driving Acute Ischemic Stroke Epidemiology trends @ Acute Ischemic Stroke Epidemiological Insights

 

Acute Ischemic Stroke Market Insights

Acute Ischemic Stroke focuses on treating the immediate acute phase to reduce the progression of the ischemia, followed simultaneously by an attempt at revascularization and reperfusion of the brain parenchyma. Further treatment includes reducing the damage and neuronal cell death caused by the ischemia and subsequent metabolic cascade brought about by the abrupt reperfusion. Finally, treatment focuses on rehabilitation and retarding the progression of vascular disease as well as the prevention of further strokes.

 

Acute Ischemic Stroke Treatment Market Landscape

• Alteplase: The AHA/ASA recommends intravenous (IV) alteplase for patients who satisfy inclusion criteria and have symptom onset or last known baseline within 3 h. IV alteplase is 0.9 mg/kg, with a maximum dose of 90 mg. The first 10% of the dose is given over the first minute as a bolus, and the remainder is given over the next 60 min. The time has been extended to 4.5 h for selected candidates. 

• BRILINTA (ticagrelor): BRILINTA is an oral, reversible, direct-acting P2Y12 receptor antagonist that inhibits platelet activation. In November 2020, the US FDA approved BRILINTA in the US to reduce the risk of stroke in patients with an acute ischemic stroke or high-risk TIA. In patients with AIS or high-risk TIA, treatment with a 180 mg loading dose of BRILINTA and then with 90 mg twice daily for up to 30 days is recommended. 

• Aspirin is recommended within 24–48 h of symptom onset. High-intensity statins (atorvastatin 80 mg daily or rosuvastatin 20 mg daily) are recommended for patients 75 years old or younger with clinical atherosclerotic cardiovascular disease. In addition, patients may be continued on statins if they were on them before the ischemic stroke. In patients with atrial fibrillation, the guidelines state it is reasonable to initiate oral anticoagulation within 4–14 days after neurological symptoms onset.

 

To know more about Acute Ischemic Stroke treatment guidelines, visit @ Acute Ischemic Stroke Treatment Market Landscape

 

Acute Ischemic Stroke Market Outlook

The report’s outlook on the Acute Ischemic Stroke market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Acute Ischemic Stroke therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Acute Ischemic Stroke drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Acute Ischemic Stroke market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Acute Ischemic Stroke Drugs Uptake

 

• Glenzocimab (ACT017): Acticor Biotech

Glenzocimab (ACT017) is a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). It inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain. GPVI is expressed exclusively by platelets and their precursors, megakaryocytes. It is a key receptor on platelets for polymerized fibrin, fibrinogen, and collagen. In July 2022, the EMA granted Priority Medicines (PRIME) status for glenzocimab, for the treatment of patients with stroke. The drug has completed a Phase Ib/IIa (ACTIMIS), and currently is conducting a Phase II/III (ACTISAVE) trial for the efficacy and safety study of glenzocimab (used as an add-on therapy on top of standard of care in the 4.5 hours following an acute ischemic stroke). Result from ACTISAVE study is expected in the second quarter of 2024 and based on this result, company plans to consult the EMA and FDA during 2024 to confirm the Phase III design that will further support registration in both Europe and the US.

 

• DM199: DiaMedica Therapeutics

DM199 is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes, including blood flow, inflammation, fibrosis, oxidative stress, and neurogenesis via a molecular mechanism that increases the production of nitric oxide and prostaglandin. In September 2021, the US FDA granted fast track designation to DM199 for treating AIS. In June 2023, the US FDA removed the clinical hold on DM199 Phase II/III trial for ischemic stroke. The drug has completed Phase I and II studies, and undergoing a Phase II/III (ReMEDy2) trial for the treatment of AIS, administered via IV/SC route.

 

• Milvexian: Bristol Myers Squibb/Janssen Pharmaceutical

Milvexian (BMS‐986177/JNJ‐70033093) is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) being studied for the prevention and treatment of major thrombotic conditions. Factor XI (FXI) amplifies thrombin generation and has a limited role in hemostasis. Targeted FXI inhibition may  reduce the burden of vascular and thromboembolic diseases while preserving hemostasis. The drug has completed Phase II trial and launched a pivotal Phase III (LIBREXIA-STROKE) clinical trial program that aims to evaluate milvexian in addition to standard of care antiplatelet therapy for stroke prevention in patients after an acute ischemic stroke.

 

Major Acute Ischemic Stroke Companies

Several companies working in the market include Abbott, Orion Corporation, Bristol-Myers Squibb, Colorado Prevention Center, Cardioxyl Pharamaceutical Inc., Novartis Pharmaceuticals, Sanjiu Medical & Pharmaceutical Co., Ltd., Boehringer Ingelheim, Innogene Kalbiotech Pte. Ltd, and others.

 

Learn more about the FDA-approved drugs for Acute Ischemic Stroke @ Drugs for Acute Ischemic Stroke Treatment

 

Scope of the Acute Ischemic Stroke Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Acute Ischemic Stroke Companies- Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medical Research Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech,, and others.
• Acute Ischemic Stroke Pipeline Therapies- UMC119-06, JTR-161, Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution, YM872 (zonampanel), t-PA (alteplase), Elezanumab, Intravenous ACT017 1000 mg, rhPro-UK, rt-PA, and others.
• Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke Market Drivers and Barriers
• Acute Ischemic Stroke Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Acute Ischemic Stroke Drugs in development @ Acute Ischemic Stroke Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Acute Ischemic Stroke (AIS) Market Overview at a Glance

4. Executive Summary of Acute Ischemic Stroke (AIS)

5. Key Events

6. Epidemiology and Patient Population

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Product

11. Acute Ischemic Stroke Emerging Therapies

12. Acute Ischemic Stroke: 7 Major Market Analysis

13. SWOT Analysis

14. KOL Views

15. Unmet Needs

16. Acute Ischemic Stroke Market Access

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/